Avalyn Pharma Inc., a clinical-stage biopharmaceutical company pioneering inhaled therapies for treating pulmonary fibrosis, is set to begin trading on the Nasdaq Global Select Market under the ticker symbol "AVLN" on April 30, 2026.
The company has priced its upsized initial public offering of 16.67 million shares of its common stock at $18.00 per share. The offering is scheduled to close on May 1, 2026, and gross proceeds to Avalyn are expected to be $300 million.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.